KEYTRUDA® (Pembrolizumab)

The FDA on June 12, 2018 approved KEYTRUDA® for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, whose tumors express PD-L1 (CPS 1 or more), as determined by an FDA-approved test. KEYTRUDA® is a product of Merck and Co., Inc.